This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mejías, A. Articles by Ramilo, O. Search for Related Content PubMed PubMed Citation Articles by Mejías, A. Articles by Ramilo, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2005, p. 4700-4707, Vol. 49, No. 11
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.11.4700-4707.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency

Department of Pediatrics, Division of Pediatric Infectious Diseases,¹ Department of Pathology, University of Texas Southwestern Medical Center at Dallas and Children's Medical Center of Dallas, Dallas, Texas,² MedImmune, Inc., Gaithersburg, Maryland³

Received 9 March 2005/ Returned for modification 20 May 2005/ Accepted 23 August 2005

Respiratory syncytial virus (RSV) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants and young children worldwide. We have previously shown in the mouse model that treatment with an anti-RSV neutralizing monoclonal antibody (MAb) against the F glycoprotein of RSV, palivizumab, decreased lung inflammation, airway obstruction, and postmethacholine airway hyperresponsiveness. MEDI-524, or Numax, is a new MAb derived from palivizumab with enhanced neutralizing activity against RSV. We compared the effects of these two MAbs on different markers of disease severity using the murine model of RSV infection. BALB/c mice were intranasally inoculated with RSV A2. Palivizumab or MEDI-524 was administered once at either 24 h before or 48 h after RSV inoculation. Regardless of the time of administration, all treated mice showed significantly decreased RSV loads in bronchoalveolar lavage samples measured by plaque assay. Only MEDI-524 given at –24 h significantly decreased lung RSV RNA loads on days 5 and 28 after RSV inoculation. Pulmonary histopathologic scores, airway obstruction, and postmethacholine airway hyperresponsiveness were significantly reduced in mice treated with MEDI-524 at 24 h before inoculation, compared with untreated controls and the other regimens evaluated. MEDI-524 was superior to palivizumab on several outcome variables of RSV disease assessed in the mouse model: viral replication, inflammatory and clinical markers of acute disease severity, and long-term pulmonary abnormalities.

This article has been cited by other articles:

• Kota, S., Sabbah, A., Chang, T. H., Harnack, R., Xiang, Y., Meng, X., Bose, S. (2008). Role of Human {beta}-Defensin-2 during Tumor Necrosis Factor-{alpha}/NF-{kappa}B-mediated Innate Antiviral Response against Human Respiratory Syncytial Virus. J. Biol. Chem. 283: 22417-22429 [Abstract] [Full Text]  
• Eckardt-Michel, J., Lorek, M., Baxmann, D., Grunwald, T., Keil, G. M., Zimmer, G. (2008). The Fusion Protein of Respiratory Syncytial Virus Triggers p53-Dependent Apoptosis. J. Virol. 82: 3236-3249 [Abstract] [Full Text]  
• Panitch, H. B. (2007). The Relationship Between Early Respiratory Viral Infections and Subsequent Wheezing and Asthma. CLIN PEDIATR 46: 392-400  
• Dall'Acqua, W. F., Kiener, P. A., Wu, H. (2006). Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn). J. Biol. Chem. 281: 23514-23524 [Abstract] [Full Text]